Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Biote Corp

BTMD ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Industrials · Professional Information Services ·

USA Micro Cap Analyst: BUY

Last Close

$1.11

▼ -5.13%

Market Cap $39.88M · Vol 15.73K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

9.98

FWD: 12.11

Market Cap

$39.88M

Micro Cap

Div Yield

N/A

EPS Growth

-110.81%

YoY

RSI (14)

47.46

Momentum

Beta

2.26

vs Market

52W High

$2.98

62.75% below

52W Low

$1.00

11.00% above

Volume

15.73K

Avg 26.17K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

80.18%

Public shares

Shariah Compliance8 STANDARDS

✗ Biote Corp (BTMD) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BTMD pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.74%

-8.26%

-50.00%

YTD

-57.31%

-60.07%

-79.17%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$192.22M
Net Income	$31.60M
Revenue Growth (YoY)	-9.48%
Gross Margin	71.46%
Operating Margin	20.35%
Net Profit Margin	16.44%
ROE	N/A
ROA · ROIC	32.68% · 48.59%

P/E Ratio	9.98
Forward P/E (FY1)	12.11
PEG Ratio	0.01
P/S	0.50
P/B	N/A
P/FCF	3.37
EPS Growth	-110.81%
Outstanding Shares	35.93M

Technical Indicators

50-Day SMA	$1.29
200-Day SMA	$1.83
RSI (14)	47.46
Beta	2.26
52-Week High	$2.98
52-Week Low	$1.00

Volume Today	15.73K
Avg Daily Volume (30D)	26.17K
Relative Volume	0.60x
Volatility (10D)	60.52
Volatility (30D)	58.45
Free Float	80.18%

Analyst Consensus

BUY

Current Price $1.11

Mean Target $2.61

52W Low$1.00 52W High$2.98

Current

Target

$1.00 $2.98

Current Analyst target

+135.32% upside potential · 4 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00ZCMCC37

ISINUS0906831039

CountryUSA

Sub-IndustryEducation & Training Information Providers

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

NIITLTD.NS NIIT Ltd -4.76% CHGG Chegg Inc +1.53% 3998.T SuRaLa Net Co Ltd +0.86% SPGI S&P Global Inc. +1.28% MCO Moody's Corporation +1.04%

Company Profile

biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.